Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report

Apatinib is a novel oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved by clinical trials to be effective and safe for patients with chemotherapy-refractory gastric cancer. To date, there is no study or case report on apatinib treatment for...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Linghui, Wang, Yue, Lu, Wenbin, Liu, Qian, Wu, Jie, Jin, Jianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359124/
https://www.ncbi.nlm.nih.gov/pubmed/28352185
http://dx.doi.org/10.2147/OTT.S126471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359124/
https://www.ncbi.nlm.nih.gov/pubmed/28352185
http://dx.doi.org/10.2147/OTT.S126471

Ejemplares similares